Publications from Our Collaboratory
COLLABORATORY OF AIDS RESEARCHERS FOR ERADICATION (CARE) PUBLICATIONS
Last Updated: October 17 2020
Stuelke EL, James KS, Kirchherr JL, Allard B, Baker C, Kuruc JD, Gay CL, Margolis DM, Archin NM. Measuring the Inducible, Replication-Competent HIV Reservoir Using an Ultra-Sensitive p24 Readout, the Digital ELISA Viral Outgrowth Assay. Front Immunol. 2020 8. Pubmed Link: 32849659
Dashti A, Waller C, Mavigner M, Schoof N, Bar KJ, Shaw GM, Vanderford T, Liang S, Lifson J, Dunham RM, Ferrari G, Tuyishime M, Lam CK, Nordstrom JL, Margolis DM, Silvestri G, Chahroudi A. SMAC mimetic plus triple combination bispecific HIVxCD3 DART® molecules in SHIV.C.CH505-infected, ART-suppressed rhesus macaques. J Virol. 2020 8. Pubmed Link: 32817214
Walters LC, McMichael AJ, Gillespie GM. Detailed and atypical HLA-E peptide binding motifs revealed by a novel peptide exchange binding assay. Eur J Immunol. 2020 7. Pubmed Link: 32716529
Tuyishime M, Garrido C, Jha S, Moeser M, Mielke D, LaBranche C, Montefiori D, Haynes BF, Joseph S, Margolis DM, Ferrari G. Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. J Clin Invest. 2020 6. Pubmed Link: 32584790
Falcinelli SD, Shook-Sa BE, Dewey MG, Sridhar S, Read J, Kirchherr J, James KS, Allard B, Ghofrani S, Stuelke E, Baker C, Roan NR, Eron JJ, Kuruc JD, Ramirez C, Gay C, Mollan KR, Margolis DM, Adimora AA, Archin NM. Impact of biological sex on immune activation and frequency of the latent HIV reservoir during suppressive antiretroviral therapy. J Infect Dis. 2020 6. Pubmed Link: 32496542
Pollara J, Edwards RW, Jha S, Lam CK, Liu L, Diedrich G, Nordstrom JL, Huffman T, Pickeral JA, Denny TN, Permar SR, Ferrari G. Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules. Front Immunol. 2020 5. Pubmed Link: 32373131
Turner AW, Dronamraju R, Potjewyd F, James KS, Winecoff DK, Kirchherr JL, Archin NM, Browne EP, Strahl BD, Margolis DM, James LI. Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal. ACS Infect Dis. 2020 4. Pubmed Link: 32347704
Maxwell JW, Falcinelli SD, Nefedov A, Dorfmeier C, Wu G, Dewey M, Webber AL, Archin NM, Margolis DM, Hazuda DJ, Barnard RJO, Howell BJ. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat. J Virol. 2020 4. Pubmed Link: 32295913
Harper J, Gordon S, Chan CN, Wang H, Lindemuth E, Galardi C, Falcinelli SD, Raines SLM, Read JL, Nguyen K, McGary CS, Nekorchuk M, Busman-Sahay K, Schawalder J, King C, Pino M, Micci L, Cervasi B, Jean S, Sanderson A, Johns B, Koblansky AA, Amrine-Madsen H, Lifson J, Margolis DM, Silvestri G, Bar KJ, Favre D, Estes JD, Paiardini M. CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption. Nat Med. 2020 4. Pubmed Link: 32284611
Tang Y, Woodward BO, Pastor L, George AM, Petrechko O, Nouvet FJ, Haas DW, Jiang G, Hildreth JEK. Endogenous Retroviral Envelope Syncytin Induces HIV-1 Spreading and Establishes HIV Reservoirs in Placenta. Cell Rep. 2020 4. Pubmed Link: 32234485
Margolis DM, Archin NM, Cohen MS, Eron JJ, Ferrari G, Garcia JV, Gay CL, Goonetilleke N, Joseph SB, Swanstrom R, Turner AW, Wahl A. Curing HIV: Seeking to Target and Clear Persistent Infection. Cell. 2020 3. Pubmed Link: 32220311
Gay CL, Kuruc JD, Falcinelli SD, Warren JA, Reifeis SA, Kirchherr JL, James KS, Dewey MG, Helms A, Allard B, Stuelke E, Gamble A, Plachco A, Gorelick RJ, Eron JJ, Hudgens M, Garrido C, Goonetilleke N, DeBenedette MA, Tcherepanova IY, Nicolette CA, Archin NM, Margolis DM. Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection. Sci Rep. 2020 3. Pubmed Link: 32198428
Stone M, Rosenbloom D, Bacchetti P, Deng X, Dimapasoc M, Keating S, Bakkour S, Richman D, Mellors J, Deeks S, Lai J, Beg S, Siliciano J, Pagliuzza A, Chomont N, Lackman-Smith C, Ptak RG, Busch MP; Reservoir Assay Validation and Evaluation Network (RAVEN) Study Group. Assessing suitability of next-generation viral outgrowth assays as proxies for classic QVOA to measure HIV-1 latent reservoir size. J Infect Dis. 2020 3. Pubmed Link: 32147687
James KS, Trumble I, Clohosey ML, Moeser M, Roan NR, Adimora AA, Joseph SB, Archin NM, Hudgens M, Soriano-Sarabia N. Measuring the contribution of γδ T cells to the persistent HIV reservoir. AIDS. 2020 11. Pubmed Link: 31764074
Nixon CC, Mavigner M, Sampey GC, Brooks AD, Spagnuolo RA, Irlbeck DM, Mattingly C, Ho PT, Schoof N, Cammon CG, Tharp GK, Kanke M, Wang Z, Cleary RA, Upadhyay AA, De C, Wills SR, Falcinelli SD, Galardi C, Walum H, Schramm NJ, Deutsch J, Lifson JD, Fennessey CM, Keele BF, Jean S, Maguire S, Liao B, Browne EP, Ferris RG, Brehm JH, Favre D, Vanderford TH, Bosinger SE, Jones CD, Routy JP, Archin NM, Margolis DM, Wahl A, Dunham RM, Silvestri G, Chahroudi A, Garcia JV. Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo. Nature. 2020 1. Pubmed Link: 31969707
McBrien JB, Mavigner M, Franchitti L, Smith SA, White E, Tharp GK, Walum H, Busman-Sahay K, Aguilera-Sandoval CR, Thayer WO, Spagnuolo RA, Kovarova M, Wahl A, Cervasi B, Margolis DM, Vanderford TH, Carnathan DG, Paiardini M, Lifson JD, Lee JH, Safrit JT, Bosinger SE, Estes JD, Derdeyn CA, Garcia JV, Kulpa DA, Chahroudi A, Silvestri G. Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8(+) cells. Nature. 2020 1. Pubmed Link: 31969705
Bauer AM, Ziani W, Lindemuth E, Kuri-Cervantes L, Li H, Lee FH, Watkins M, Ding W, Xu H, Veazey R, Bar KJ. Novel Transmitted/Founder Simian-Human Immunodeficiency Viruses for Human Immunodeficiency Virus Latency and Cure Research. J Virol. 2020 1. Pubmed Link: 31969435
Goswami R, Nelson AN, Tu JJ, Dennis M, Feng L, Kumar A, Mangold J, Mangan RJ, Mattingly C, Curtis AD 2nd, Obregon-Perko V, Mavigner M, Pollara J, Shaw GM, Bar KJ, Chahroudi A, De Paris K, Chan C, Van Rompay KKA, Permar SR. Analytical Treatment Interruption after Short-Term Antiretroviral Therapy in a Postnatally Simian-Human Immunodeficiency Virus-Infected Infant Rhesus Macaque Model. mBio. 2019 9. Pubmed Link: 31488511
Bar KJ, Coronado E, Hensley-McBain T, O’Connor MA, Osborn JM, Miller C, Gott TM, Wangari S, Iwayama N, Ahrens CY, Smedley J, Moats C, Lynch RM, Haddad EK, Haigwood NL, Fuller DH, Shaw GM, Klatt NR, Manuzak JA. Simian-Human Immunodeficiency Virus SHIV.CH505 Infection of Rhesus Macaques Results in Persistent Viral Replication and Induces Intestinal Immunopathology. J Virol. 2019 6. Pubmed Link: 31217249
Nelson AN, Goswami R, Dennis M, Tu J, Mangan RJ, Saha PT, Cain DW, Curtis AD, Shen X, Shaw GM, Bar K, Hudgens M, Pollara J, De Paris K, Van Rompay KKA, Permar SR. Simian-Human Immunodeficiency Virus SHIV.CH505-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes. J Virol. 2019 5. Pubmed Link: 31092583
Rosenbloom DIS, Bacchetti P, Stone M, Deng X, Bosch RJ, Richman DD, Siliciano JD, Mellors JW, Deeks SG, Ptak RG, Hoh R, Keating SM, Dimapasoc M, Massanella M, Lai J, Sobolewski MD, Kulpa DA, Busch MP; Reservoir Assay Validation and Evaluation Network (RAVEN) Study Group. Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size. PLoS Comput Biol. 2019 4. Pubmed Link: 30978183
Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV. 2019 3. Pubmed Link: 30885693
Garrido C, Tolstrup M, Søgaard OS, Rasmussen TA, Allard B, Soriano-Sarabia N, Archin NM, Margolis DM. In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals. AIDS. 2019 3. Pubmed Link: 30830886
Richman DD, Huang K, Lada SM, Sun X, Jain S, Massanella M, Menke B. Replication competence of virions induced from CD4+ lymphocytes latently infected with HIV. Retrovirology. 2019 2. Pubmed Link: 30770748
Pinzone MR, VanBelzen DJ, Weissman S, Bertuccio MP, Cannon L, Venanzi-Rullo E, Migueles S, Jones RB, Mota T, Joseph SB, Groen K, Pasternak AO, Hwang WT, Sherman B, Vourekas A, Nunnari G, O’Doherty U. Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion. Nat Commun. 2019 2. Pubmed Link: 30760706
Beliakova-Bethell N, Mukim A, White CH, Deshmukh S, Abewe H, Richman DD, Spina CA. Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation. J Biol Chem. 2019 2. Pubmed Link: 30745362
Abrahams MR, Joseph SB, Garrett N, Tyers L, Moeser M, Archin N, Council OD, Matten D, Zhou S, Doolabh D, Anthony C, Goonetilleke N, Karim SA, Margolis DM, Pond SK, Williamson C, Swanstrom R. The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. Sci Transl Med. 2019 10. Pubmed Link: 31597754
Falcinelli SD, Ceriani C, Margolis DM, Archin NM. New Frontiers in Measuring and Characterizing the HIV Reservoir. Front Microbiol. 2019 1. Pubmed Link: 31921056
Lada SM, Huang K, VanBelzen DJ, Montaner LJ, O’Doherty U, Richman DD. Quantitation of Integrated HIV Provirus by Pulsed-Field Gel Electrophoresis and Droplet Digital PCR. J Clin Microbiol. 2018 9. Pubmed Link: 30232127
Walters LC, Harlos K, Brackenridge S, Rozbesky D, Barrett JR, Jain V, Walter TS, O’Callaghan CA, Borrow P, Toebes M, Hansen SG, Sacha JB, Abdulhaqq S, Greene JM, Früh K, Marshall E, Picker LJ, Jones EY, McMichael AJ, Gillespie GM. Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding. Nat Commun. 2018 8. Pubmed Link: 30087334
Honeycutt JB, Garcia JV. Humanized mice: models for evaluating NeuroHIV and cure strategies. J Neurovirol. 2018 8. Pubmed Link: 28831774
Papasavvas E, Lada SM, Joseph J, Yin X, Liu Q, Azzoni L, Mounzer K, Kostman JR, Richman D, Montaner LJ. Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV. AIDS. 2018 7. Pubmed Link: 30045057
Clutton GT, Jones RB. Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure. Front Immunol. 2018 7. Pubmed Link: 29988382
Garrido C, Clohosey ML, Whitworth CP, Hudgens M, Margolis DM, Soriano-Sarabia N. γδ T cells: an immunotherapeutic approach for HIV cure strategies. JCI Insight. 2018 6. Pubmed Link: 29925697
Salantes DB, Zheng Y, Mampe F, Srivastava T, Beg S, Lai J, Li JZ, Tressler RL, Koup RA, Hoxie J, Abdel-Mohsen M, Sherrill-Mix S, McCormick K, Overton ET, Bushman FD, Learn GH, Siliciano RF, Siliciano JM, Tebas P, Bar KJ. HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. J Clin Invest. 2018 6. Pubmed Link: 29911997
Honeycutt JB, Liao B, Nixon CC, Cleary RA, Thayer WO, Birath SL, Swanson MD, Sheridan P, Zakharova O, Prince F, Kuruc J, Gay CL, Evans C, Eron JJ, Wahl A, Garcia JV. T cells establish and maintain CNS viral infection in HIV-infected humanized mice. J Clin Invest. 2018 6. Pubmed Link: 29863499
White CH, Beliakova-Bethell N, Lada SM, Breen MS, Hurst TP, Spina CA, Richman DD, Frater J, Magiorkinis G, Woelk CH. Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment. Front Immunol. 2018 5. Pubmed Link: 29706951
Abdel-Mohsen M, Kuri-Cervantes L, Grau-Exposito J, Spivak AM, Nell RA, Tomescu C, Vadrevu SK, Giron LB, Serra-Peinado C, Genescà M, Castellví J, Wu G, Del Rio Estrada PM, González-Navarro M, Lynn K, King CT, Vemula S, Cox K, Wan Y, Li Q, Mounzer K, Kostman J, Frank I, Paiardini M, Hazuda D, Reyes-Terán G, Richman D, Howell B, Tebas P, Martinez-Picado J, Planelles V, Buzon MJ, Betts MR, Montaner LJ. CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Sci Transl Med. 2018 4. Pubmed Link: 29669853
Garrido C, Abad-Fernandez M, Tuyishime M, Pollara JJ, Ferrari G, Soriano-Sarabia N, Margolis DM. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo. J Virol. 2018 3. Pubmed Link: 29593039
Ruggiero A, Cozzi-Lepri A, Beloukas A, Richman D, Khoo S, Phillips A, Geretti AM; ERAS Study Group. Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy. Open Forum Infect Dis. 2018 3. Pubmed Link: 29507867
Jiang G, Nguyen D, Archin NM, Yukl SA, Méndez-Lagares G, Tang Y, Elsheikh MM, Thompson GR 3rd, Hartigan-O’Connor DJ, Margolis DM, Wong JK, Dandekar S. HIV latency is reversed by ACSS2-driven histone crotonylation. J Clin Invest. 2018 2. Pubmed Link: 29457784
Ke R, Conway JM, Margolis DM, Perelson AS. Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design. JCI Insight. 2018 10. Pubmed Link: 30333308
Massanella M, Yek C, Lada SM, Nakazawa M, Shefa N, Huang K, Richman DD. Improved assays to measure and characterize the inducible HIV reservoir. EBioMedicine. 2018 10. Pubmed Link: 30316868
Bradley T, Ferrari G, Haynes BF, Margolis DM, Browne EP. Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. Cell Rep. 2018 10. Pubmed Link: 30282021
Dubé K, Dee L, Evans D, Sylla L, Taylor J, Brown B, Miller V, Corneli A, Skinner A, Greene SB, Tucker JD, Rennie S. Perceptions of Equipoise, Risk-Benefit Ratios, and “Otherwise Healthy Volunteers” in the Context of Early-Phase HIV Cure Research in the United States: A Qualitative Inquiry. J Empir Res Hum Res Ethics. 2018 10. Pubmed Link: 28984168
Lee SK, Zhou S, Baldoni PL, Spielvogel E, Archin NM, Hudgens MG, Margolis DM, Swanstrom R. Quantification of the Latent HIV-1 Reservoir Using Ultra Deep Sequencing and Primer ID in a Viral Outgrowth Assay. J Acquir Immune Defic Syndr. 2017 9. Pubmed Link: 27683060
Wu G, Swanson M, Talla A, Graham D, Strizki J, Gorman D, Barnard RJ, Blair W, Søgaard OS, Tolstrup M, Østergaard L, Rasmussen TA, Sekaly RP, Archin NM, Margolis DM, Hazuda DJ, Howell BJ. HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. JCI Insight. 2017 8. Pubmed Link: 28814661
Sung JA, Sholtis K, Kirchherr J, Kuruc JD, Gay CL, Nordstrom JL, Bollard CM, Archin NM, Margolis DM. Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells. EBioMedicine. 2017 8. Pubmed Link: 28803740
Turner AW, Margolis DM. Chromatin Regulation and the Histone Code in HIV Latency. Yale J Biol Med. 2017 6. Pubmed Link: 28656010
Yek C, Massanella M, Peling T, Lednovich K, Nair SV, Worlock A, Vargas M, Gianella S, Ellis RJ, Strain MC, Busch MP, Nugent CT, Richman DD. Evaluation of the Aptima HIV-1 Quant Dx Assay for HIV-1 RNA Quantitation in Different Biological Specimen Types. J Clin Microbiol. 2017 6. Pubmed Link: 28592548
Ferrari G, Pollara J, Tomaras GD, Haynes BF. Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection. J Infect Dis. 2017 5. Pubmed Link: 28520963
Margolis DM, Archin NM. Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents. J Infect Dis. 2017 5. Pubmed Link: 28520964
Margolis DM. Towards an HIV Cure: a View of a Developing Field. J Infect Dis. 2017 5. Pubmed Link: 28520965
Garner SA, Rennie S, Ananworanich J, Dube K, Margolis DM, Sugarman J, Tressler R, Gilbertson A, Dawson L. Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations. J Virus Erad. 2017 4. Pubmed Link: 28435691
Honeycutt JB, Thayer WO, Baker CE, Ribeiro RM, Lada SM, Cao Y, Cleary RA, Hudgens MG, Richman DD, Garcia JV. HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy. Nat Med. 2017 4. Pubmed Link: 28414330
Dubé K, Sylla L, Dee L, Taylor J, Evans D, Bruton CD, Gilberston A, Gralinski L, Brown B, Skinner A, Weiner BJ, Greene SB, Corneli A, Adimora AA, Tucker JD, Rennie S. Research on HIV cure: Mapping the ethics landscape. PLoS Med. 2017 12. Pubmed Link: 29220353
Cummins NW, Rizza S, Litzow MR, Hua S, Lee GQ, Einkauf K, Chun TW, Rhame F, Baker JV, Busch MP, Chomont N, Dean PG, Fromentin R, Haase AT, Hampton D, Keating SM, Lada SM, Lee TH, Natesampillai S, Richman DD, Schacker TW, Wietgrefe S, Yu XG, Yao JD, Zeuli J, Lichterfeld M, Badley AD. Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study. PLoS Med. 2017 11. Pubmed Link: 29182633
Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeyer CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SG. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Med. 2017 11. Pubmed Link: 29112956
Kessing CF, Nixon CC, Li C, Tsai P, Takata H, Mousseau G, Ho PT, Honeycutt JB, Fallahi M, Trautmann L, Garcia JV, Valente ST. In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a “Block-and-Lock” Strategy for HIV-1 Treatment. Cell Rep. 2017 10. Pubmed Link: 29045830
Margolis DM, Koup RA, Ferrari G. HIV antibodies for treatment of HIV infection. Immunol Rev. 2017 1. Pubmed Link: 28133794
Ferrari G, Pollara J, Tomaras G, Haynes B. Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection. JID 2017:215 (Suppl 3) S152-S159 PMCID: PMC5410976
https://www.ncbi.nlm.nih.gov/pubmed/28520963
Honeycutt JB, Thayer WO, Baker CE, Ribeiro RM, Lada SM, Cao Y, Cleary RA, Hudgens MG, Richman DD, Garcia JV. HIV Persistence in tissue macrophages of humanized mice during ART. Nat Med 2017 23(5): 638-643. PMID: 28414330 PMCID: PMC5419854
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419854
Margolis DM, Archin NM. Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents. JID 2017:215 (Suppl 3) S111-S118. PMID: 28520964 PMCID: PMC5410986
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410986
Lee et al. Quantification of the Latent HIV-1 Reservoir Using Ultra Deep Sequencing and Primer ID in a Viral Outgrowth Assay. JAIDS 2017 PMID:27683060 PMCID:PMC5233602. NIHMS817501
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5233602
Yek C, Massanella M, Peling T, Lednovich K, Nair SV, Worlock A, Vargas M, Gianella S, Ellis RJ, Strain MC, Busch MP, Nugent CT, Richman DD. Evaluation of the Aptima HIV-1 Quant Dx Assay for HIV-1 RNA Quantitation in Different Biological Specimen Types, JCM 2017 55(8): 2544-2553.
Martins LJ, Bonczkowski P, Spivak AM, De Spiegelaere W, Novis CL, DePaula-Silva AB, Malatinkova E, Typsteen W, Bosque A, Vanderkerckhove L, Planelles V. Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus. AIDS Res Hum Retroviruses. 2015 Jul 14.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/26171776
Reardon B, Beliakova-Bethell N, Spina CA, Singhania A, Margolis DM, Richman DR, Woelk CH. Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells. AIDS. 2015 Aug 7.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/26258524
Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4+ T Cells from Aviremic Patients. Antimicrob Agents Chemother. 2015 Jul 13. pii: AAC.01077-15.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/26169416
Sung JA, Lam S, Garrido C, Archin N, Rooney CM, Bollard CM, Margolis DM. Expanded Cytotoxic T-Cell Lymphocytes Target the Latent HIV Reservoir. J Infect Dis. 2015 Jul 15;212(2):258-63.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25589335
Sung JA, Pickeral J, Liu L, Stanfield-Oakley SA, Lam CYK, Garrido C, Pollara J, LaBranche C, Bonsignori M, Moody MA, Yang Y, Parks R, Archin N, Allard B, Kirchherr J, Kuruc JD, Gay CL, Cohen MS, Ochsenbauer C, Soderberg K, Liao HX, Montefiori D, Moore P, Johnson S, Koenig S, Haynes BF, Nordstrom JL, Margolis DM, Ferrari G. Dual-Affinity Re-Targeting proteins direct T cell–mediated cytolysis of latently HIV-infected cells.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/26413868
Abdel-Mohsen M, Wang C, Strain MC, Lada SM, Deng X, Cockerman LR, Pilcher C, Hecht FM, Liegler T, Richman DD, Deeks SG, Pillai SK. Select host restriction factors are associated with HIV persistence during antiretroviral therapy. AIDS 2015; 29(4):411-20.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25602681
Ananworanich J, Dubé K, Chomont N. How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs? Curr Opin HIV/AIDS 2015 Jan;10(1):18-28. doi: 10.1097/COH.0000000000000122.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25415421
Archin NM, Sung JM, Garrido C, Soriano-Serabia N, Margolis DM. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol. 2014 Nov;12(11):750-64. doi: 10.1038/nrmicro3352.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25402363
Bonczkowski P, Spiegelaere WD, Bosque A, White C, Nuffel AV, Malatinkova E, Kiselinova M, Trypsteen W, Witkowski W, Vermeire J, Verhasselt B, Martins L, Woelk C, Planelles V, Vandekerckhove L. Replication competent virus as an important source of bias in HIV latency models utilizing single round viral constructs. Retrovirology 2014, 11: 70. doi:10.1186/s12977-014-0070-3.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25142072
Bruner KM, Hosmane NN, Siliciano RF. Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol. 2015 Apr;23(4):192-203
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25747663
Buehler DC, Marsden MD, Shen S, Toso DB, Wu X, Loo JA, Zhou H, Kickhoefer VA, Wender PA, Zack JA, Rome LH. Bioengineered vaults: self-assembling proteins shell-lipophilic core nanoparticles for drug delivery. ACS Nano 2014; (Web): 25 Jul 2014 DOI: 10.1021/nn5002694.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25061969
Chen Y, Zhang L, Estarás C, Choi SH, Moreno L Jr, Karn J, Moresco JJ, Yates JR 3rd, Jones KA. A gene-specific role for the Ssu72 RNAPII CTD phosphatase in HIV-1 Tat transactivation. Genes Dev. 2014 Oct 15;28(20):2261-75.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25319827
Cockerham LR, Siliciano JR, Sinclair E, O’Doherty U, Palmer S, Yukl SA, Strain MC, Chomont N, Hecht FM, Siliciano RF, Richman DD, Deeks SG. CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells. PLoS One. 2014 Oct 23;9(10):e110731.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25340755
Crooks, AM, Bateson R, Cope AB, Dahl NP, Griggs MK, Kuruc JD, Gay CL, Eron JJ, Margolis DM, Bosch RJ, Archin NM. Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies. J Infect Dis 2015 Apr 15. pii: jiv218. [Epub ahead of print]
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25877550
Dahabieh MS, Battivelli E, Verdin E. Understanding HIV latency: the road to an HIV cure. Annu Rev Med. 2015; 66:407-21.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25587657
Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL, Hao H, Zhang H, Margolick JB, Gurer C, Murphy AJ, Valenzuela DM, Yancopoulos GD, Deeks DG, Strowig T, Kumar P, Siliciano JD, Zalzberg SL, Flavell RA, Shan L, Siliciano RF. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. 2015 Jan 15;517(7534):381-5.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25561180
Dubé K, Henderson GE, Margolis DM. Framing expectations in early HIV cure research. Trends in Microbiology October 2014, Vol. 22, No. 10 doi.org/10.1016/j.tim.2014.08.003.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25280965
Eifler TT, Shao W, Bartholomeeusen K, Fujinaga K, Jäger S, Johnson JR, Luo Z, Krogan NJ, Peterlin BM. Cyclin-dependent kinase 12 increases 3′ end processing of growth factor-induced c-FOS transcripts. Mol Cell Biol. 2015 Jan;35(2):468-78.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25384976
Fujinaga K, Luo Z, Schaufele F, Peterlin BM. Visualization of positive transcription elongation factor b (P-TEFb) activation in living cells. J Biol Chem. 2015 Jan 16;290(3):1829-36.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25492871
Fujinaga K, Luo Z, Peterlin BM. Genetic analysis of structure and function of 7SK small nuclear ribonucleoprotein (7SK snRNP) in cells. J Biol Chem 2014, 289: 21181-90 doi: 10.1074/jbc.M114.557751.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24917669
Hill AL, Rosenbloom DIS, Fu F, Nowak MA, Siliciano RF. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. PNAS 2014, doi/10.1073/pnas.1406663111.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25097264
Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, Li F, Luo B, Alvarez-Carbonell D, Garcia-Mesa Y, Karn J, Mo X, Khalili K. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11461-6.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25049410
Kim M, Hosmane NN, Bullen CK, Capoferri A, Yang HC, Siliciano JD, Siliciano RF. A primary CD4+ T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence. Nat Protoc. 2014 Dec;9(12):2755-70.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25375990
Laird GM, Bullen K, Rosenbloom DIS, Martin AR, Hill AL, Durand CM, Siliciano JD, Siliciano RF. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest. 2015 Mar 30. pii: 80142.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25822022
Lam S, Sung J, Cruz C, Castillo-Caro P, Ngo M, Garrido C, Kuruc J, Archin N, Rooney C, Margolis DM, Bollard C. Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy. Mol Ther. 2015 Feb;23(2):387-95.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25366030
Marsden MD, Zack JA. Studies of retroviral infection in humanized mice. Virology. 2015 Feb 11. pii: S0042-6822(15)00029-X.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25680625
Marsden MD, Zack JA. Double trouble: HIV latency and CTL escape. Cell Host Microbe. 2015 Feb 11;17(2):141-2.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25674977
Marsden MD, Zack JA. Neutralizing the HIV reservoir. Cell 2014 Aug 28;158(5):971-2. doi: 10.1016/j.cell.2014.08.010.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25171398
Martinez-Torres F, Nochi T, Wahl A, Garcia JV, Denton PW. Hypogammaglobulineria in BLT humanized mice – an animal model of primary antibody deficiency. PLoS One 2014 Oct 1;9(10):e108663.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25271886
Metcalf Pate KA, Pohlmeyer CW, Walker-Sperling VE, Foote JB, Najarro KM, Cryer CG, Salgado M, Gama L, Engle EL, Shirk EN, Queen SE, Chioma S, Vermillion MS, Bullock B, Li M, Lyons CE, Adams RJ, Zink MC, Clements JE, Mankowski JL, Blankson JN. A murine viral outgrowth assay to detect residual HIV-1 in patients with undetectable viral loads. J Infect Dis. 2015 Apr 15. pii: jiv230.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25883388
Murry JP, Godoy J, Mukim A, Swann C, Bruce JW, Ahlquist P, Bosque A, Planelles V, Spina CA, Young JAT. Sulfonation pathway inhibitors block reactivation of latent HIV-1. Virology 2014, 471-473:1-12. doi: 10.1016/j.virol.2014.08.016.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25310595
Persaud D, Patel K, Karalius B, Rainwater-Lovett K, Ziemniak C, Ellis A, Chen YH, Richman DD, Siberry GK, Van Dyke RB, Burchett S, Seage III GR, Luzuriaga K for the Pediatric HIV/AIDS Cohort Study. Influence of age at virologic control on peripheral blood HIV reservoir size and serostatus in perinatally infected adolescents. JAMA Pediatr 2014; Oct 6. doi: 10.1001/jamapediatrics.2014.1560.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25286283
Shan L, Siliciano RF. Unraveling the relationship between microbial translocation and systemic immune activation in HIV infection. J Clin Invest. 2014 Jun;124(6):2368-71.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24837427
Shimizu S, Ringpis GE, Marsden MD, Cortado RV, Wilhalme HM, Elashoff D, Zack JA, Chen ISY, Sung An D. RNA-I mediated CCR5 knockdown provides HIV-1 resistance to memory T cells in humanized BLT mice. Mol Ther Nucleic Acids 2015 Feb 17;4:e227.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25689223
Soriano-Sarabia N, Bateson RE, Dahl NP, Crooks AM, Kuruc JD, Margolis DM, Archin NA. The quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells. J Virol 2014 doi:10.1128/JVI.01900-14.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25253353
Sung JA, Lam S, Garrido C, Archin N, Rooney CM, Bollard CM, Margolis DM. Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir. J Infect Dis. 2015 Jan 13. pii: jiv022.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25589335
Thompson CG, Bokhart MT, Sykes C, Adamson L, Fedoriw Y, Luciw P, Muddiman DC, Kashuba AD, Rosen EP. Mass Spectrometry Imaging Reveals Heterogeneous Efavirenz Distribution within Putative HIV Reservoirs. Antimicrob Agents Chemother. 2015 Mar 2. pii: AAC.04952-14.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25733502
Wang C, Abdel-Mohsen M, Strain M, Lada S, Yukl S, Cockerman L, Pilcher C, Hecht F, Sinclair E, Liegler T, Richman D, Deeks S, Pillai S. Decreased HIV-1 transcription in CCR5-Delta-32 Heterozygotes on suppressive antiretroviral therapy. J Infect Dis 2014 Jun 16. pii: jiu338.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24935955
Abreu CM, Price SL, Shirk EN, Cunha RD, Pianowski LF, Clements JE, Tanuri A, Gama L. Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLoS One 2014; 9(5): e97257.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24827152
Archin NM, Bateson R, Tripathy M, Crooks AM, Yang F, Dahl NP, Kearney MF, Anderson EM, Coffin JM, Strain MC, Richman DD, Robertson KR, Kashuba AD, Bosch RJ, Hazuda DJ, Kuruc JD, Eron JJ, Margolis DM. HIV-1 expression within resting CD4 T-cells following multiple doses of Vorinostat. J Infect Dis 2014 Sep 1;210(5):728-35. doi: 10.1093/infdis/jiu155.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24620025
Barry JA, Robichaud G, Bokhart MT, Thompson C, Sykes C, Kashuba AD, Muddiman DC. Mapping Antiretroviral drugs in tissue by IR-MALDESI MSI coupled to the Q exactive and comparison with LC-MS/MS SRM assay. J Am Soc Mass Spectrom 2014 [Epub ahead of print].
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24744212
Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nature Medicine 2014. doi:10.1038/nm.3489.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24658076
Calvanese V, Chavez L, Laurent T, Ding S, Verdin E. Dual-color HIV reporters trace a population of latently infected cells and enable their purification. Virology 2013; 446(1-2): 283-92.
PubMed: www.ncbi.nlm.nih.gov/pubmed/24074592
Chaillon A, Gianella S, Massanella Luna M, Little SJ, Richman DD, Mehta SR. A case study cluster demonstrating the relationship between HLA concordance and virologic and disease outcomes in HIV infection. Virology 2014 449; 104-8.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24418543
Dar RD, Hosmane NN, Arkin MR, Siliciano RF, Weinberger LS. Screening for noise in gene expression identifies drug synergies. Science 2014 Jun 20;344(6190):1392-6. doi: 10.1126/science.1250220.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24903562
Denton PW, Long JM, Wietgrefe SW, Sykes C, Spagnuolo RA, Snyder OD, Perkey K, Archin NM, Choudhary SK, Yang K, Hudgens MG, Pastan I, Haase AT, Kashuba AD, Berger EA, Margolis DM, Garcia JV. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathogens 2014; 10(1): e1003872.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24415939
Doitsh G, Galloway NLK, Geng X, Monroe KM, Zepeda O, Yang Z, Hunt PW, Hatano H, Sowinski S, Greene WC. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 2013; doi:10.1038/nature12940.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24356306
Duverger A, Wolschendorf F, Anderson JC, Wagner D, Bosque A, Shishido T, Jones J, Planelles V, Willey C, Cron RQ, Kutsch O. Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation. J Virol 2013 [Epub ahead of print]
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24155393
Geng X, Doitsh G, Yang Z, Galloway NLK, Greene WC. Efficient delivery of lentiviral vectors into resting human CD4 T cells. Gene Therapy 2014:444-9. doi: 10.1038/gt.2014.5.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24572792
Gianella S, Massanella M, Richman DD, Little SJ, Spina CA, Vargas MV, Lada SM, Daar ES, Dube MP, Haubrich RH, Morris SR, Smith DM, California Collaborative Treatment Group 592 Team. Cytomegalovirus replication in semen is associated with higher levels of proviral HIV RNA and CD4+ T cell activation during antiretroviral treatment. J Virol 2014 88(4): 7818-27.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24789781
Hatano H, Strain MC, Scherzer R, Baccheti P, Wentworth D, Hoh R, Martin JN, McCune JM, Neaton JD, Tracy RP, Hsue PY, Richman DD, Deeks SG. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis 2013; 208(9): 1436-42.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23975885
Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenblood DIS, Lai J, Blankson JN, Siliciano JD, Siliciano RF. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013; 155(3): 540-51.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24243014
Honeycutt JD, Sheridan PA, Matsushima GK, Garcia JV. Humanized mouse models for HIV-1 infection in the CNS. J Neurovirol 2014 Nov 4. [Epub ahead of print]
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25366661
Honeycutt JB, Wahl A, Archin N, Choudhary S, Margolis DM, Garcia JV. HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T- cell-only mouse (TOM) model. Retrovirology 2013; 10: 121.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24156277
Jadlowsky JK, Wong JY, Graham AC, Dobrowolski C, Devor RL, Adams MD, Fujinaga K, Karn J. Negative elongation factor is required for the maintenance of proviral latency but does not induce promoter-proximal pausing of RNA polymerase II on the HIV long terminal repeat. Mol Cell Biol 2014; 34(11).
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24636995
Liu J, Sisk JM, Gama L, Clements JE, Witwer KW. Tristetrapolin expression and microRNA-mediated regulation during simian immunodeficiency virus infection of the central nervous system. Mol Brain 2013; 6(1): 40.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24103357
Liu P, Xiang Y, Fujinaga K, Bartholomeeusen K, Nilson K, Price DH, Peterlin BM. Release of P-TEFb from 7SK snSNP activates HEXIM1 transcription. Journal of Biol Chem 2014; 289(14): 9918-25. doi: 10.1074/jbc.M113.539015.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24515107
Luzuriaga K, Tabak B, Garber M, Chen YH, Ziemniak C, McManus MM, Murray D, Strain MC, Richman DC, Chun TW, Cunningham CK, Persaud DP. HIV-1 proviral reservoirs decay continuously under sustained virologic control in early-treated HIV-1 infected children. J Infect Dis 2014. 210(10):1529-38. doi: 10.1093/infdis/jiu297
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24850788
Marsden MD, Zack JA. HIV/AIDS eradication. Bioorg Med Chem Lett. 2013 Jul 15;23(14):4003-10. doi: 10.1016/j.bmcl.2013.05.032.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23735743
Marsden MD, Kovochich M, Suree N, Shimizu S, Mehta R, Cortado R, Bristol G, An DS, Zack JA. HIV latency in the humanized BLT mouse. J Virol 2012;86(1):339-47. doi: 10.1128/JVI.06366-11.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/22072769
Massanella M, Ouchi D, Marfil S, Llibre JM, Puertas MC, Buzón MJ, Richman DD, Orna E, Stevenson M, Gatell JM, Domingo P, Negredo E, Martinez-Picado J, Clotet B, Blanco J. Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals. PLoS One. 2014 Dec 2;9(12):e114142.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25462535
Mbonye U, Karn J. Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure. Virology 2014; 454-55: 328-39.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24565118
McManamy MEM, Hakre S, Verdin EM, Margolis DM. Therapy for latent human immunodeficiency virus type 1 infection: the role of histone deacetylase inhibitors. Antiviral Chemistry and Chemotherapy 2014; 23(4): 145-9. doi: 10.3851/IMP2551.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24318952
Monroe KM, Yang Z, Johnson JR, Geng X, Doitsh G, Krogran NJ, Greene WC. IFI16 sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science. 2014; 343(6169):428-32.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24356113
Nixon CC, Vatakis DN, Reichelderfer SN, Dixit D, Kim SG, Uittenbogaart CH, Zack JA. HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice. Blood 2013; 122(13):2195-204. doi: 10.1182/blood-2013-04-496950.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23886835
Novis CL, Archin NM, Buzon MJ, Verdin E, Round JL, Lichterfeld M, Margolis DM, Planelles V, Bosque A. Reactivation of latent HIV-1 in central memory CD4+ T cells through TLR-1/2 stimulation. Retrovirology 2013; 10: 119.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24156240
Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Chun TW, Strain M, Richman DD, Luzuriaga K. Absence of detectable HIV-1 viremia following treatment cessation in an infant. N Engl J Med 369(19): 1828-35.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24152233
Ruelas CS, Greene WC. An integrated overview of HIV-1 latency. Cell 2013 Oct 24;155(3):519-29.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24243012
Russell JN, Clements JE, Gama L. Quantitation of gene expression in formaldehyde-fixed and fluorescence-activated sorted cells. PLoS One 2013; 8(9):e73849.doi: 10.1371/journal/pone.0073849.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24023909
Salgado M, Swanson MD, Pohlmeyer CW, Buckheit RW 3rd, Wu J, Archin NM, Wiliams TM, Margolis DM, Siliciano RF, Garcia JV, Blankson JN. HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice. J Virol 2014; 88(6):3340-52. doi: 10.1128/JVI.03380-13 2014 Jan 3.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24390323
Shan L, Xing S, Yang HC, Zhang H, Margolick JB, Siliciano RF. Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells. J Antimicrob Chemther 2013. doi:10.1093/jac/dkt338.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23999005
Sherrill-Mix S, Lewinski MK, Famiglietti M, Bosque A, Malani N, Ocwieja KE, Berry CC, Looney D, Shan L, Agosto LM, Pace MJ, Siliciano RF, O’Doherty U, Guatelli J, Planelles V, Bushman V, Bushman FD. HIV latency and integration site placement in five cell-based models. Retrovirology 2013; 10(90). doi: 10.1186/1742-4690-10-90.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23953889
Siliciano JD, Siliciano RF. HIV-1 eradication strategies: design and assessment. Review. Curr Opin HIV AIDS; 8(4): 318-25.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23698561
Sisk JM, Witwer KW, Tarwater PM, Clements JE. SIV replication is directly downregulated by four antiviral miRNAs. Retrovirology 2013; 10(1): 95.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23988154
Spina CA, Anderson J Archin NM, Bosque A, Chan J, Famiglietti M, Greene WC, Kashuba A, Lewin SR, Margolis DM, Mau M, Ruelas D, Saleh S, Shirakawa K, Siliciano RF, Singhania A, Soto PC, Terry VH, Verdin E, Woelk C, Wooden S, Xing S, Planelles V. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathogens 2013; 9(12): e1003834. doi: 10.1371/journal.ppat.1003834.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24385908
Tatro ET, Purnajo I, Richman DD, Smith DM, Gianella S. Antibody response to Achromobacter xylosoxidans during HIV infection is associated with lower CD4 levels and increased lymphocyte activation. Clin Vaccine Immunol 2013. doi:10.1128/CVI.00553-13.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24173027
Thompson CG, Cohen MS, Kashuba AD. Antiretroviral pharmacology in mucosal tissues. J Acquir Immune Defic Syndr 2013 Jul;63 Suppl 2:S240-7. doi:10.1097/QAI.0b013e3182986ff8.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23764642
Wagner GA, Pacold ME, Kosakovsky Pond PL, Caballero G, Chaillon A, Rudolph AE, Morris SR, Little SJ, Richman DD, Smith DM. Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States. J Infect Dis 2014; 209(7): 1032-8.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24273040
Wagner GA, Pacold ME, Vigil E, Cabellero G, Morris SR, Kosakovsky Pond SL, Little SL, Richman DD, Gianella S, Smith DM. Using ultradeep pyrosequencing to study HIV-1 coreceptor usage in primary and dual infection. J Infect Dis 2013; 208(2): 271-4.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23599311
Wahl A, Garcia JV. The use of BLT humanized mice to investigate the immune reconstitution of the gastrointestinal tract. J Immunol Methods. 2014 Aug;410:28-33.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24952245
Witwer KW, McAlexander MA, Queen SE, Adams RJ. Real-time quantitative PCR and ddPCR for plan miRNA in mammalian blood provide little evidence for general uptake of dietary miRNAs. RNA Biology 2013; 10(7): 1080-6.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23770773
Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487(7408):482-5. doi: 10.1038/nature11286. Erratum in: Nature. 2012 Sep 20;489(7416):460.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/22837004
Banerjee C, Archin NM, Michaels D, Belkina AC, Denis GV, Bradner J, Sebastiani P, Margolis DM, Montano M. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol. 2012 Dec;92(6):1147-54. doi:10.1189/jlb.0312165.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/22802445
Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM. Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J Biol Chem 2012;287(43):36609-16. doi: 10.1074/jbc.M112.410746. Erratum in: J Biol Chem. 2013 Apr 26;288(17):12214.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/22952229
Bartholomeeusen K, Fujinaga K, Xiang Y, Peterlin BM. Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J Biol Chem. 2013 May 17;288(20):14400-7. doi: 10.1074/jbc.M113.464834.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23539624
Beliakova-Bethell N, Zhang JX, Singhania A, Lee V, Terry VH, Richman DD, Spina CA, Woelk CH. Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells. AIDS 2013;27(1):29-37. doi: 10.1097/QAD.0b013e32835b3e26.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23221426
Boehm D, Calvanese V, Dar RD, Xing S, Schroeder S, Martins L, Aull K, Li PC, Planelles V, Bradner JE, Zhou MM, Siliciano RF, Weinberger L, Verdin E, Ott M. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 2013;12(3):452-62. doi: 10.4161/cc.23309.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23255218
Boehm D, Conrad RJ, Ott M. Bromodomain proteins in HIV infection. Viruses 2013 Jun 21;5(6):1571-86. doi: 10.3390/v5061571.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23793227
Budhiraja S, Famiglietti M, Bosque A, Planelles V, Rice AP. Cyclin T1 and CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 latency in primary resting memory CD4+ T cells. J Virol. 2013 Jan;87(2):1211-20. doi: 10.1128/JVI.02413-12.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23152527
Deng K, Zink C, Clements JE, Siliciano RF. A quantitative measurement of antiviral activity of anti-human immunodeficiency virus type 1 drugs against SIV: dose-response curve slope strongly influences class-specific inhibitory potential. J Virol 2012; 86(20):11368-72.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/22875968
Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012; 37(3): 377-88.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/22999944
Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, Bosch RJ, Lai J, Chioma S, Emad F, Abdel-Mohsen M, Hoh R, Hecht F, Hunt P, Somsouk M, Wong J, Johnston R, Siliciano RF, Richman DD, O’Doherty U, Palmer S, Deeks SG, Siliciano JD. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathogens 2013 Feb;9(2):e1003174. doi: 10.1371/journal.ppat.1003174.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23459007
Hightower GK, May SJ, Perez-Santiago J, Pacold ME, Wagner GA, Little SJ, Richman DD, Mehta SR, Smith DM, Pond SL. HIV-1 clade B pol evolution following primary infection. PLoS One 2013; 8(6):e68188.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23840830
Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, Miller M, Vella S, Schmitz JE, Ahlers J, Richman DD, Sekaly RP. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013; 15;381(9883):2109-17. doi: 10.1016/S0140-6736(13)60104-X.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23541541
Knipe DM, Lieberman PM, Jung JU, McBride AA, Morris KV, Ott M, Margolis D, Nieto A, Nevels M, Parks RJ, Kristie TM. Snapshots: chromatin control of viral infection. Virology 2013;435(1):141-56. doi: 10.1016/j.virol.2012.09.023.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23217624
Laird GM, Eisele EE, Rabi SA, Lai J, Chioma S, Blankson JN, Siliciano JD, Siliciano RF. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathogens 2013; 9(5):e1003398.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23737751
Le T, Wright EJ, Smith DM, He W, Catano G, Okulicz JF, Young JA, Clark RA, Richman DD, Little SJ, Ahuja SK. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med. 2013 Jan 17;368(3):218-30. doi: 10.1056/NEJMoa1110187.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23323898
Mbonye UR, Gokulrangan G, Datt M, Dobrowolski C, Cooper M, Chance MR, Karn JR. Phosphorylation of CDK9 at Ser175 enhances HIV transcription and is a marker of activated P-TEFb in CD4(+) T lymphocytes. PLoS Pathogens 2013;9(5):e1003338.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23658523
Nochi T, Denton PW, Wahl A, Garcia JV. Cryptopatches are essential for the development of human GALT. Cell Rep. 2013 Jun 27;3(6):1874-84. doi: 10.1016/j.celrep.2013.05.037.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23791525
Ravimohan S, Gama L, Engle EL, Zink MC, Clements JE. Early emergence and selection of a SIV-LTR C/EBP site variant in SIV-infected macaques that increases virus infectivity. PLoS One 2012;7(8):e42801. doi: 10.1371/journal.pone.0042801. Erratum in: PLoS One 2013;8(3). doi: 10.1371/annotation/050af66e-a935-46e6-96ec-5ac7e0fc4dfc.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/22952612
Razooky BS, Gutierrez E, Terry VH, Spina CA, Groisman A, Weinberger LS. Microwell devices with finger-like channels for long-term imaging of HIV-1 expression kinetics in primary human lymphocytes. Lap Chip 2012; 12(21): 4305-12.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/22976503
Rouzioux C, Richman D. How to best measure HIV reservoirs? Curr Opin HIV AIDS. 2013 May;8(3):170-5. doi: 10.1097/COH.0b013e32835fc619.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23564004
Shan L, Rabi A, Laird GM, Eisele EE, Zhang, Margolick JB, Siliciano RF. A novel PCR assay for quantification of HIV-1 RNA. J Virol 2013.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23536672
Shirakawa K, Chavez L, Hakre S, Calvanese V, Verdin E. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 2013; 21(6): 277-85.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23517573
Sisk JM, Clements JE, Witwer KW. miRNA profiles of monocyte-lineage cells are consistent with complicated roles in HIV-1 restriction. Viruses 2012;4(10):1844-64. doi: 10.3390/v4101844. Erratum in: Viruses. 2013 Mar;5(3):901.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23202444
Strain MC, Lada SM, Luong T, Rought SE, Gianella S, Terry VH, Spina CA, Woelk CH, Richman DD. Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One 2013; 8(4):e55943.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23573183
Taube R, Peterlin BM. Lost in transcription: molecular mechanisms that control HIV latency. Viruses 2013; 21: 902-27.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23518577
Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, Eisele E, Haase A, Ho YC, Hutter G, Justement JS, Keating S, Lee TH, Li P, Murray D, Palmer S, Pilcher C, Pillai S, Price RW, Rothenberger M, Schacker T, Siliciano R, Sinclair E, Strain M, Wong J, Richman D, Deeks SG. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathogens 2013; 9(5):e1003347.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23671416
Denton PW, Olesen R, Choudhary SK, Archin NM, Wahl A, Swanson MD, Chateau M, Nochi T, Krisko JF, Spagnuolo RA, Margolis DM, Garcia JV. Generation of HIV latency in humanized BLT mice. J Virol 2012 Jan;86(1):630-4. doi: 10.1128/JVI.06120-11.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/22013053
Hakre S, Chavez L, Shirakawa K, Verdin E. HIV latency: experimental systems and molecular models. FEMS Microbiol Rev 2012;36(3):706-16. doi: 10.1111/j.1574-6976.2012.00335.x.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/22372374
Mbonye U, Karn J. Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr HIV Res 2011; 9(8): 544-67.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/22211660
Planelles V, Wolschendorf F, Kutsch O. Facts and fiction: cellular models for high throughput screening for HIV-1 reactivating drugs. Curr HIV Res 2011; 9(8): 568-78.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/22211661
Witwer KW, Watson AK, Blankson JN, Clements JE. Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients. Retrovirology 2012;9:5. doi: 10.1186/1742-4690-9-5.
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/22240256
Ruggiero A, Cozzi-Lepri A, Beloukas A, Richman D, Khoo S, Phillips A, Geretti AM; ERAS Study Group. Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive